UNSPSC 51152300: Combination parasympathomimetics (cholinergics)

This classification denotes combination drugs and preparations that mimic the effects of parasympathetic nervous system activity and which have affects on cholinergic systems and/or the acetylcholine life-cycle, and which therefore bear the terms PARASYMPATHOMIMETICS and CHOLINERGICS. Typical of this class is the drug atropine. Typical combination parasympathomimetic or cholinergic constituents are edrophonium and sodium chloride.

UNSPSC 51152300 Combination parasympathomimetics (cholinergics) is a Class code that does not align with the state and local opportunities currently posted under it. The recent solicitations tagged to this code are for naloxone procurement and direct-to-manufacturer prescription programs — neither of which are cholinergic medications or pharmaceutical ingredients. The mismatch suggests either a cataloging error in the source data or misclassification by the issuing bodies. State and local procurement activity under this code shows little relevant current opportunity.

The two posted opportunities are unrelated to each other and to the code's nominal scope: Seminole County, Florida issued an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline (note: the deadline date appears internally inconsistent with the posting date), while the Texas Health and Human Services Commission issued an RFI on April 3, 2026 regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to explore vendor capacity for direct pharmaceutical contracting outside traditional pharmacy benefit manager and group purchasing organization channels. Neither opportunity reflects cholinergic medications or the chemical scope the UNSPSC code nominally describes. Without additional opportunities in the source supporting actual combination parasympathomimetic procurement, this code presents no actionable market signal for the business development audience pursuing state and local pharmaceutical or medical supply contracts.